BABA-W (9988.HK) › Analysis

BABA-W (9988.HK) stock analysis, February 3, 2026: BABA-W tests $168-170 resistance after Qwen hits 100M users

Published February 3, 2026 · 9988.HK chart, levels and live analysis

Key Updates

BABA-W rebounded 2.47% to $166.10 since the February 2nd report, recovering from the $162.10 support level but remaining below the critical $168-170 resistance zone that was breached during the prior decline. The recovery was supported by no material negative news developments, suggesting technical consolidation rather than fundamental deterioration. The stock maintains a strong YTD gain of 16.48% and 42.09% over six months, though momentum has moderated from the January rally that peaked at $173.50.

Current Trend

BABA-W demonstrates a consolidative pattern following the sharp rally from late 2025. The YTD performance of +16.48% reflects sustained investor interest, while the 6-month gain of 42.09% confirms the structural uptrend initiated in Q4 2025. Recent price action shows a volatile pattern: +11.48% over one month but -2.24% over five days, indicating profit-taking after the January surge. The stock is currently testing the $168-170 resistance zone from below, having failed to hold this level in early February. Support has established at $162-165, with the next major support at $153-155 based on the November 2025 low following the White House memo allegations.

Investment Thesis

The investment thesis centers on Alibaba's strategic transformation into an AI-driven technology conglomerate, backed by CEO Eddie Wu's $53 billion commitment to AI infrastructure. The company is executing a comprehensive AI monetization strategy through: (1) integration of core services (Taobao, Alipay, Fliggy) into the Qwen AI app, which has reached 100 million users; (2) potential IPO of chipmaking unit T-Head to unlock value and access capital for semiconductor development; (3) expansion of cloud services leveraging AI accelerators and potential access to Nvidia H200 chips; and (4) healthcare AI applications through Alibaba Health. This multi-pronged approach positions Alibaba to capture value across the AI ecosystem while reducing dependence on traditional e-commerce. However, the thesis faces headwinds from regulatory scrutiny, geopolitical tensions evidenced by the White House military support allegations, and competitive pressure in the AI space from ByteDance and other domestic rivals.

Thesis Status

The investment thesis remains intact and is strengthening with tangible execution milestones. The T-Head IPO preparation represents a significant value unlock opportunity, particularly given strong investor demand for Chinese chip IPOs as evidenced by MetaX Integrated Circuits and Moore Threads offerings. The Qwen AI app achieving 100 million users and securing integration with flagship services demonstrates rapid adoption, though it trails ByteDance's Doubao at 172 million monthly active users. The potential approval of Nvidia H200 chip imports would materially enhance Alibaba's cloud computing capabilities, with the company expressing interest in ordering over 200,000 units. The securities fraud investigation announced in January represents a persistent overhang but has not resulted in material regulatory action to date. The core challenge remains converting AI investments into incremental revenue and profitability, particularly as the company navigates Beijing's live-streaming regulations impacting e-commerce operations.

Key Drivers

Near-term catalysts include: (1) T-Head IPO execution, which could unlock substantial value and validate Alibaba's semiconductor capabilities, particularly following T-Head's contract with China Unicom for Pingtouge AI accelerators; (2) Nvidia H200 chip import approval, expected as early as Q1 2026, enabling significant cloud infrastructure upgrades and competitive positioning against US rivals; (3) Qwen AI platform monetization, as the integration of Taobao shopping, Alipay payments, and travel services creates agentic AI capabilities that could drive transaction volumes; (4) Healthcare AI expansion, with Alibaba Health surging 19% on optimism about AI applications in China's healthcare sector; and (5) resolution or escalation of the securities fraud investigation related to alleged military support claims, which remains a material risk factor.

Technical Analysis

BABA-W is consolidating in the $162-170 range after the January rally to $173.50. The current price of $166.10 sits at the midpoint of this consolidation zone, with immediate resistance at $168-170 representing the breakdown level from February 2nd. A decisive break above $170 would target the January high of $173.50 and potentially the $180 psychological level. Support is established at $162-165, reinforced by the 50-day moving average, with secondary support at $153-155 from the November 2025 post-White House memo low. The 6-month chart shows a clear uptrend with higher lows at $117 (August 2025) and $153 (November 2025), supporting the bullish structure. Volume patterns indicate institutional accumulation during dips below $165, suggesting strong demand at lower levels. The stock's ability to hold above $162 during the recent pullback demonstrates resilience and sets up a potential retest of $170-173 resistance.

Bull Case

Bear Case

Get a message when the 9988.HK picture changes — the agent team watches the levels and the news for you.Create a free account

More 9988.HK analyses